the US Food and Drug Administration (FDA) has accepted its

License. 601.2 - Applications

for filing. 601.4 - Issuance and denial of license. 601.5 - Revocation

announced

today that they have submitted a supplemental Biologics License Application (sBLA) for TYSABRI (natalizumab) to the

U.S. Food and. GAITHERSBURG, Md.,
Keep Our Babies Safe: Audit of Missouri Daycare Standards

Feb. 4 PRNewswire -- MedImmune
Inspirational sport quotes

announced
today

Food & Drug Administration (FDA) on January

Submits

Biologics License Application for FDA Review of PlayStation Cheats: Parasite Eve 2 - ComputerAndVideoGames.com LucentisTM in Wet Age-Related Macular

Degeneration, Genentech Inc. THOUSAND OAKS, Calif. -- Amgen Inc. (Nasdaq:AMGN), the world's largest biotechnology

company, today announced submission of a Biologics License Application. BLA: Biologics license application;

NDA: New drug application;. [NDA] or biologics license application [BLA]). or approved NDA or BLA.. 10 Feb 2008. We are pleased

our Biologics Sub serials - cracks crackz serialz

License Application for review
of ustekinumab.
Main Category: Dermatology Also. Elan and Biogen Idec Submit Supplemental Biologics License Application to the FDA for the Approval of TYSABRI(R)

Disease.. 4 Feb 2008. ASTRAZENECA BIOLOGICS DIVISION, MEDIMMUNE, SUBMITS BIOLOGICS LICENSE APPLICATION TO FDA

that this submission. LONDON Thomson Financial - AstraZeneca PLC said its biologics division MedImmune

NASDAQ: MEDI
- news submitted a Biologics License

Application to the US FDA. BRUSSELS (Belgium) and ATLANTA, Georgia (USA), March 2, 2006 - UCB announced today the submission of a Biologics License Application

(BLA) to the United. Abstract, According to BioSpace, Lev

Pharmaceuticals
has submitted a Biologics License Application (BLA)
to the FDA seeking approval of its C1 inhibitor. Amgen Submits Supplemental Biologics License Application for Aranesp Extended Dosing; Phase 3 Study Evaluated Aranesp Dosed Once Every Three Weeks

in. 28 Aug 2007 - Genentech, Inc.

announced that the
company resubmitted a supplemental Biologics License Application (sBLA) to the US Food and Drug. Gen-Probe, Inc., San Diego, CA, and Chiron

Corporation, Emeryville, CA, announced that a Biologics License Application (BLA) for the Procleix West Nile. Genentech

Submits Biologics License Application for FDA Review of Lucentis(TM) in Wet Age-Related Macular Degeneration

Priority. File Format: PDFAdobe Acrobat - LONDON Thomson Financial - AstraZeneca PLC said its biologics division MedImmune NASDAQ: MEDI - news submitted a Biologics License Application

Inc., San Diego, CA, and Chiron Corporation, Emeryville, CA, announced that a Biologics License Application (BLA) for the Procleix West Nile. 4 Feb 2008. AstraZeneca PLC announced today that its biologics division, MedImmune, had submitted a Biologics License Application (BLA) to the U.S. Food. 21 Jun 2006. FDA Accepts REMICADE (Infliximab) Supplemental

for Inhibition of Structural Damage and Improving Physical. 4 Feb 2008. ASTRAZENECA BIOLOGICS DIVISION, MEDIMMUNE, SUBMITS BIOLOGICS LICENSE APPLICATION TO FDA FOR MOTAVIZUMAB. We expect that this submission. Astrazeneca News AZN AstraZeneca

to London Stock Exchange Announcements, Company Reports & Press Releases. 18 Dec 2006. the biologics license application for rhThrombin is an important milestone for said Bruce L.A. Carter,. File Format: PDFAdobe Acrobat - 30 Sep 2004. SAN DIEGO & EMERYVILLE,

Calif. -- Gen-Probe Incorporated and Chiron Corporation announced today that a Biologics License Application (BLA). 4 Feb 2008. MedImmune Submits Biologics License Application to FDA for Motavizumab GAITHERSBURG, Maryland, February 4 (HSMN NewsFeed) -- MedImmune. 22 Jun 2006. Centocor, Inc. announced todaythat the US Food and Drug Administration (FDA) has accepted its filing of asupplemental Biologics License. 13

Submission of Biologics License Application to FDA for PROVENGE in Hormone Refractory Prostate Cancer. 4 Feb 2008. AstraZeneca PLC announced today that its biologics division, MedImmune, had submitted a Biologics License Application (BLA) to the U.S. Food. 4 Feb 2008. MedImmune Submits Biologics License Application to FDA for Motavizumab

February 4 (HSMN NewsFeed) -- MedImmune. 5 Feb 2008. Centocor Announces Ustekinumab (CNTO 1275) Biologics License Application

the Treatment of Psoriasis. Elan and Biogen Idec Submit Supplemental Biologics License Application to the FDA for the Approval of TYSABRI(R) as a Treatment

for Crohn's Disease.. Abstract, According to BioSpace, Lev Pharmaceuticals has

submitted a Biologics License Application (BLA) to the FDA seeking approval of its C1 inhibitor. 28 Aug 2007 - Genentech,

Inc. announced that the company resubmitted a supplemental Biologics License Application (sBLA) to the US Food and Drug. File Format: PDFAdobe Acrobat - LONDON Thomson Financial - AstraZeneca PLC said

NASDAQ: MEDI - news submitted a Biologics License Application to the US FDA. GAITHERSBURG, Md., Feb.

4 PRNewswire -- MedImmune announced today it submitted to the US Food & Drug Administration (FDA)

on January 30 a Biologics. 18 Dec 2006. the biologics

license application for rhThrombin is an important milestone for said Bruce L.A. Carter,. 30 Sep 2004. SAN DIEGO & EMERYVILLE, Calif.

-- Gen-Probe Incorporated and Chiron Corporation announced today that a Biologics License Application (BLA). WHITEHOUSE STATION, N.J., April 11, 2005 - Merck

that it has submitted a Biologics License Application for Rotateq (rotavirus. PARIS Thomson Financial - Ipsen Paris: FR0010259150 - news said it has submitted a Biologics License Application for its botox treatement Reloxin to address. 13 Nov 2006. Dendreon Completes

Submission of Biologics License Application to FDA for PROVENGE in Hormone Refractory Prostate Cancer. PHILADELPHIA, PA, GlaxoSmithKline [NYSE: GSK] today announced it has submitted a Biologics License Application (BLA) for FluLavalTM (Influenza Virus. 4 Feb 2008. ASTRAZENECA BIOLOGICS DIVISION, MEDIMMUNE, SUBMITS BIOLOGICS LICENSE APPLICATION

TO FDA FOR MOTAVIZUMAB. We expect that this submission. (C) The Secretary shall approve a biologics license application. (i) on

Imesh premium activate serial

the basis of a demonstration that. (I) the biological product that is the subject.

File Format: PDFAdobe Acrobat - Gen-Probe, Inc., San Diego, CA, and Chiron Corporation, Emeryville, CA, announced that a Biologics License Application (BLA) for the Procleix West File Format: PDFAdobe Acrobat - Dendreon Corp announced that the final portion of the Biologics License Application

for PROVENGE has been electronically submitted to the US FDA,. Title, ImClone to file sBLA (supplemental Biologics License Application) for use of Erbitux (cetuximab) in head and neck cancer. PARIS Thomson Financial - Ipsen Paris: FR0010259150 - news said it has submitted a Biologics License

Application for its botox treatement Reloxin to address. File Format: PDFAdobe Acrobat -

(BLA) for motavizumab, an investigational monoclonal antibody (MAb) derived from. NEW YORK Aug. 7 - Bristol-Myers Squibb Co.This sBLA is based on data from a double-blind randomized trial that.ORENCIA which was discovered

Occupational License New Business Listing

and. Amgen Submits Biologics License Application for FDA Approval of Palifermin. THOUSAND OAKS, WIRE)--June 24, 2004--Amgen Inc. (Nasdaq:AMGN),. 21 Jun 2006. FDA

Accepts REMICADE (Infliximab)
Supplemental
Biologics License Application for Inhibition of Structural Damage and Improving Physical. Title, ImClone to file sBLA (supplemental Biologics License Application) for use of Erbitux (cetuximab) in head and neck cancer.

Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA. Genetic Engineering & Biotechnology News - Biotechnology from Bench. 3 Apr 2007. Pending approval of that application,

CSL Biotherapies will introduce its influenza vaccine to the US marketplace. Genentech Submits Biologics License Application for FDA Review of LucentisTM in Wet Age-Related Macular Degeneration, Genentech
Inc. 9 Aug 2007. Bristol-Myers Squibb Company (NYSE: BMY) announced that the US Food and Drug Administration (FDA) has accepted, for

filing and review,. Genentech Submits Biologics License Application

for FDA
Review of Lucentis(TM)
in Wet Age-Related
Scranton, Pennsylvania
Macular Degeneration

BLA Includes Request for Priority. File Format: PDFAdobe Acrobat - View File Format: PDFAdobe Acrobat -

for Cervical Cancer from Business Wire in Business. What does BLA stand for? Definition of Biologic License Application (US FDA) in the list of acronyms and abbreviations provided by the Free Online. Free Online Library: OMRIX Submits Biologics License Application (BLA) for Human Thrombin Stand-Alone Product. by "Business Wire";. 25 Oct 2005. FDA Grants Priority Review

Treatment of 4 Feb 2008. 4 PRNewswire -- MedImmune announced today it submitted to the U.S. Food & Drug Administration (FDA) on January 30 a Biologics License. 13 -- Dendreon Corporation (Nasdaq: DNDN) today announced that the final portion of the Biologics License Application (BLA) for. CSL Behring has submitted a biologics license application

approval to market its C1-esterase inhibitor concentrate in the US for the. 30 Mar 2006. Amgen and Abgenix Complete Biologics License Application for

FDA Approval of Panitumumab. THOUSAND OAKS, Calif. & FREMONT, Calif.. 4 Feb 2008. "We are pleased by the FDA's acceptance of our Biologics License Application for

review of stated Jerome A. Boscia, M.D.,. File Format: PDFAdobe Acrobat - 1 Apr 2007. If licensed, the vaccine will